From the Research
Amlodipine may actually alleviate diabetic peripheral neuropathy, rather than causing it, as suggested by the most recent and highest quality study. The study published in 2025 1 found that amlodipine besylate, a first-line clinical antihypertensive drug, can alleviate DPN-like pathologies in mice by acting as a GPR40 agonist. This is in contrast to previous concerns that amlodipine may cause peripheral neuropathy.
Key Points to Consider
- Amlodipine's effects on calcium channels in peripheral nerves were previously thought to potentially alter normal nerve function and signaling, leading to neuropathy symptoms 2, 3.
- However, the most recent study suggests that amlodipine may have a beneficial effect on diabetic peripheral neuropathy, making it a potential treatment option 1.
- The study found that amlodipine attenuated inflammatory responses and ameliorated mitochondrial dysfunction in DPN mice, highlighting its potential for treating this condition.
- Other studies have shown that amlodipine is a first-line antihypertensive agent with good efficacy and safety, and strong evidence for cardiovascular event reduction 4, 5.
Recommendations
- Amlodipine should be considered as a potential treatment for diabetic peripheral neuropathy, rather than a cause of it.
- Patients taking amlodipine for hypertension or angina who experience neuropathy symptoms should consult their healthcare provider to discuss the potential benefits and risks of continuing or adjusting their medication.
- Regular monitoring of symptoms and possibly nerve conduction studies may be recommended to assess any progression or improvement of neuropathic symptoms.